Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as ...
The BUZZ Index returned 1.75% during the month of January compared to a return of 1.45% for the S&P 500 Index during the same ...
NAR VANCOUVER, BC, Feb. 27, 2026 /CNW/ – North Arrow Minerals Inc. (TSXV: NAR) (“North Arrow” or the “Company”) is pleased to ...
Researchers at University of California San Diego School of Medicine have developed a new, easy-to-use blood test score that ...
Volt Carbon Technologies Inc. (TSXV: VCT) (OTCQB: TORVF) (“Volt Carbon” or the “Company”) announces that it will be exhibiting at PDAC 2026 ...
ONCE Capital increased its stake in NuScale Power during the fourth quarter as AI-driven data centers boost demand for reliable electricity. NuScale is developing small modular nuclear reactors ...
Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for ...
Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...
A new blood test can help the early identification of liver scarring in liver disease. Learn more about this study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results